Sacubitril/valsartan for the management of heart failure: a perspective viewpoint on current evidence
Current international guidelines recommend switching angiotensin converting enzyme
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …
Cardiovascular outcomes with sacubitril-valsartan in heart failure: emerging clinical data
JJ Cuthbert, P Pellicori, AL Clark - Therapeutics and Clinical Risk …, 2020 - Taylor & Francis
One of the defining features of heart failure (HF) is neurohormonal activation. The renin-
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …
Impact of sacubitril/valsartan on patient outcomes in heart failure: evidence to date
S Akbar, N Kabra, WS Aronow - Therapeutics and Clinical Risk …, 2020 - Taylor & Francis
With an estimated 6.2 million adults affected in the USA, heart failure remains a leading
cause of morbidity, mortality, and health-care costs, despite the use of guideline-based …
cause of morbidity, mortality, and health-care costs, despite the use of guideline-based …
Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry
Aims To compare baseline characteristics of patients with heart failure with reduced ejection
fraction (HFrEF) initiated on sacubitril/valsartan compared with patients continued on …
fraction (HFrEF) initiated on sacubitril/valsartan compared with patients continued on …
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …
Sacubitril/valsartan in heart failure: latest evidence and place in therapy
E Kaplinsky - Therapeutic advances in chronic disease, 2016 - journals.sagepub.com
Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at
high risk for HF progression and death. Sacubitril/valsartan (previously known as LCZ696) is …
high risk for HF progression and death. Sacubitril/valsartan (previously known as LCZ696) is …
Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis
E Charuel, T Menini, S Bedhomme… - Pharmacology …, 2021 - Wiley Online Library
This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …
failure, with a focus on important patient outcomes. A systematic review was conducted of …
[HTML][HTML] Effectiveness of sacubitril/valsartan in heart failure with reduced ejection fraction using real-world data: an updated systematic review and meta-analysis
A Rahhal, M Kasem, B Orabi, F Hamou… - Current Problems in …, 2023 - Elsevier
We conducted a systematic review and meta-analysis to assess all-cause mortality and
heart failure (HF) hospitalization with sacubitril/valsartan (S/V) compared to standard HF …
heart failure (HF) hospitalization with sacubitril/valsartan (S/V) compared to standard HF …
[HTML][HTML] Rationale for and practical use of sacubitril/valsartan in the patient's journey with heart failure and reduced ejection fraction
Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has
become a milestone in the treatment of patients with chronic heart failure (HF) with reduced …
become a milestone in the treatment of patients with chronic heart failure (HF) with reduced …
Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
A Abdin, M Schulz, U Riemer, B Hadëri… - ESC Heart …, 2022 - Wiley Online Library
Heart failure (HF) treatment has changed substantially over the last 30 years, leading to
significant reductions in mortality and hospital admissions in patients with HF with reduced …
significant reductions in mortality and hospital admissions in patients with HF with reduced …